Nutra Pharma Corp.
NPHC
$0.00
$0.000.00%
OTC PK
| 06/30/2023 | 03/31/2023 | 09/30/2022 | 09/30/2022 | 06/30/2022 | |
|---|---|---|---|---|---|
| Revenue | 82.41% | 598.20% | 465.80% | 465.80% | 196.39% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 82.41% | 598.20% | 465.80% | 465.80% | 196.39% |
| Cost of Revenue | 32.07% | 260.42% | 328.13% | 328.13% | 575.56% |
| Gross Profit | 185.81% | 1,221.79% | 610.42% | 610.42% | 37.67% |
| SG&A Expenses | -28.00% | 58.70% | -41.62% | -41.62% | -19.45% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -19.54% | 67.48% | -34.97% | -34.97% | -8.03% |
| Operating Income | 46.56% | -29.28% | 53.84% | 53.84% | 22.25% |
| Income Before Tax | 56.77% | -111.82% | -96.26% | -96.26% | -119.21% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 56.77% | -111.82% | -96.26% | -96.26% | -119.21% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 56.77% | -111.82% | -96.26% | -96.26% | -119.21% |
| EBIT | 46.56% | -29.28% | 53.84% | 53.84% | 22.25% |
| EBITDA | 47.23% | -29.73% | 54.74% | 54.74% | 23.24% |
| EPS Basic | 100.00% | -114.29% | -95.24% | -95.24% | -120.00% |
| Normalized Basic EPS | -- | -100.00% | -100.00% | -100.00% | -100.00% |
| EPS Diluted | 100.00% | -133.33% | -100.00% | -100.00% | -150.00% |
| Normalized Diluted EPS | -- | -100.00% | -100.00% | -100.00% | -100.00% |
| Average Basic Shares Outstanding | 1.72% | 3.37% | 4.16% | 4.16% | 3.04% |
| Average Diluted Shares Outstanding | 1.72% | -47.59% | 23.11% | 23.11% | -36.50% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |